Adverse events associated with eteplirsen: A disproportionality analysis using the 2016–2023 FAERS data

Background: Eteplirsen (Exondys 51) is an orphan drug approved for the treatment of Duchenne muscular dystrophy (DMD), having received accelerated approval from the U.S. Food and Drug Administration (FDA) in 2016. The primary aim of this study is to closely monitor adverse events (AEs) associated wi...

Full description

Bibliographic Details

Published in:	Heliyon
Main Authors:	Zhicheng Dai, Guangming Wang, Jiafeng Zhang, Qinghua Zhao, Lei Jiang
Format:	Article
Language:	English
Published:	Elsevier 2024-07-01
Subjects:	Eteplirsen Duchenne muscular dystrophy FAERS Adverse event Disproportionality analyses
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405844024094489